{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:49:59Z","timestamp":1782208199362,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03560-0","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:46:23Z","timestamp":1774525583000},"page":"2913-2929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia\u00a0A: Results from the PREDICT Study"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct05036278","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-3268","authenticated-orcid":false,"given":"Doris V.","family":"Quon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-0240","authenticated-orcid":false,"given":"Miguel","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2997-3757","authenticated-orcid":false,"given":"Lisa","family":"Boggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-4809","authenticated-orcid":false,"given":"Fernando F.","family":"Corrales-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-7997","authenticated-orcid":false,"given":"Akshat","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-2806","authenticated-orcid":false,"given":"Mark T.","family":"Reding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-4206","authenticated-orcid":false,"given":"Janice M.","family":"Staber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5596-397X","authenticated-orcid":false,"given":"Jessica","family":"Charlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"suppl 6","key":"3560_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"4","key":"3560_CR2","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1111\/hae.14313","volume":"27","author":"PM Mannucci","year":"2021","unstructured":"Mannucci PM, Cortesi PA, Di Minno MND, San\u00f2 M, Mantovani LG, Di Minno G. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia\u00a0A. Haemophilia. 2021;27(4):e422\u201333. https:\/\/doi.org\/10.1111\/hae.14313.","journal-title":"Haemophilia"},{"issue":"6","key":"3560_CR3","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1111\/hae.14649","volume":"28","author":"V Nummi","year":"2022","unstructured":"Nummi V, Lehtinen A-E, Iorio A, Szanto T, Lassila R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia\u00a0A: comparison of factor product use, bleed rates and pharmacokinetics. Haemophilia. 2022;28(6):e237\u201344. https:\/\/doi.org\/10.1111\/hae.14649.","journal-title":"Haemophilia"},{"issue":"3","key":"3560_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/rth2.12204","volume":"3","author":"JK Yu","year":"2019","unstructured":"Yu JK, Iorio A, Edginton AN, WAPPS Co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: a scoping review. Res Pract Thromb Haemost. 2019;3(3):528\u201341. https:\/\/doi.org\/10.1002\/rth2.12204.","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"3560_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.13597","volume":"15","author":"MT Reding","year":"2017","unstructured":"Reding MT, Ng HJ, Poulsen LH, et al. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor viii. J Thromb Haemost. 2017;15(3):411\u20139. https:\/\/doi.org\/10.1111\/jth.13597.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3560_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/hae.13853","volume":"25","author":"S Lalezari","year":"2019","unstructured":"Lalezari S, Reding MT, Pabinger I, et al. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5\u00a0years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia. 2019;25(6):1011\u20139. https:\/\/doi.org\/10.1111\/hae.13853.","journal-title":"Haemophilia"},{"key":"3560_CR7","unstructured":"Kovaltry [package insert]. Bayer HealthCare Pharmaceuticals Inc; 2016."},{"key":"3560_CR8","unstructured":"Advate [package insert]. Shire US Inc; 2011."},{"key":"3560_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/PPA.S202773","volume":"13","author":"L Carroll","year":"2019","unstructured":"Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY. Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adherence. 2019;13:941\u201357. https:\/\/doi.org\/10.2147\/PPA.S202773.","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"3560_CR10","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1007\/s00277-020-04250-9","volume":"99","author":"C Ay","year":"2020","unstructured":"Ay C, Perschy L, Rejt\u00f6 J, Kaider A, Pabinger I. Treatment patterns and bleeding outcomes in persons with severe hemophilia\u00a0A and B in a real-world setting. Ann Hematol. 2020;99(12):2763\u201371. https:\/\/doi.org\/10.1007\/s00277-020-04250-9.","journal-title":"Ann Hematol"},{"issue":"1","key":"3560_CR11","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1111\/hae.12294","volume":"20","author":"S Lalezari","year":"2014","unstructured":"Lalezari S, Martinowitz U, Windyga J, et al. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia\u00a0A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia. 2014;20(1):e15-22. https:\/\/doi.org\/10.1111\/hae.12294.","journal-title":"Haemophilia"},{"issue":"suppl 1","key":"3560_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127046","volume":"134","author":"A Iorio","year":"2019","unstructured":"Iorio A, Maas Enriquez M, Delesen H, Solms A, Croteau SE, Berntorp E. Correlations between von Willebrand factor antigen levels and Factor VIII pharmacokinetics are similar across different FVIII products in patients with severe hemophilia\u00a0A. Blood. 2019;134(suppl 1):3637. https:\/\/doi.org\/10.1182\/blood-2019-127046.","journal-title":"Blood"},{"issue":"1","key":"3560_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2450\/2021.0138-21","volume":"20","author":"C Biasoli","year":"2022","unstructured":"Biasoli C, Baldacci E, Coppola A, et al. Promoting physical activity in people with haemophilia: the MEMO (Movement for persons with haEMOphilia) expert consensus project. Blood Transfus. 2022;20(1):66\u201377. https:\/\/doi.org\/10.2450\/2021.0138-21.","journal-title":"Blood Transfus"},{"issue":"6","key":"3560_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/hae.12485","volume":"20","author":"X Niu","year":"2014","unstructured":"Niu X, Poon JL, Riske B, et al. Physical activity and health outcomes in persons with haemophilia B. Haemophilia. 2014;20(6):814\u201321. https:\/\/doi.org\/10.1111\/hae.12485.","journal-title":"Haemophilia"},{"issue":"14","key":"3560_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2012.12727.","volume":"308","author":"CR Broderick","year":"2012","unstructured":"Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452\u20139. https:\/\/doi.org\/10.1001\/jama.2012.12727.","journal-title":"JAMA"},{"issue":"11","key":"3560_CR16","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935\u20139. https:\/\/doi.org\/10.1111\/jth.12672.","journal-title":"J Thromb Haemost"},{"key":"3560_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/ejh.14337","volume":"114","author":"M Chandler","year":"2025","unstructured":"Chandler M, Moulton T, Charafi L, et al. Effectiveness of damoctocog alfa pegol to treat patients with hemophilia\u00a0A enrolled in the ATHNdataset. Eur J Haematol. 2025;114:448\u201357. https:\/\/doi.org\/10.1111\/ejh.14337.","journal-title":"Eur J Haematol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03560-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03560-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03560-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:19:44Z","timestamp":1782206384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03560-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3560"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03560-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in third author affiliation.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Doris V. Quon: Bayer, Biomarin Pharmaceutical Inc., CSL Behring, Hema Biologics\/LFB, Genentech\/Roche, Novo Nordisk, Pfizer, Sanofi, Takeda. Miguel Escobar: Genentech, HEMA Biologics, LFB, Novo Nordisk, Sanofi, Takeda, uniQure, BioMarin, CSL Behring, Kedrion, NHF, Pfizer. Lisa Boggio: Regeneron, Kedrion, Novo Nordisk, Octapharma, Sanofi, Alnylam, Genentech. Fernando F. Corrales-Medina: Genentech, Novo Nordisk, Octapharma, Bayer (consultancy), Takeda, Sanofi. Akshat Jain: NovoNordisk, Sanofi, Pfizer, Bayer (Speaker); Pfizer, Beam Therapeutics (grant funding); End point adjudication committee (Beam, Genetix). Mark T. Reding: Institutional research support:\u00a0Bayer, Be Biopharma, Biomarin. Advisory board:\u00a0Bayer, CSL Behring, Genentech, HEMA Biologics, Novo Nordisk, Sanofi, Spark, Takeda; Speaker bureau:\u00a0Bayer, CSL Behring, Sanofi, Takeda. Robert F. Sidonio, Jr: Advisory board: Bayer, Genentech, Roche, HEMA Biologics, LFB, Novo Nordisk, Sanofi, Sobi, Takeda, Octapharma, Alnylam and HEMAb. IIS: Takeda, LFB, HEMA Biologics, Octapharma. Other: ATHN Chair, HFA medical advisor. Janice Staber: Bayer, BioMarin, Genentech, NovoNordisk, Sanofi. Jessica Charlet: Current Bayer employee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The results presented in this article are based on the PREDICT study. All procedures performed in the study were in accordance with the ethical standards of the local institutional review board (IRB) for each site and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The central IRB was WCG and their reference number is 20215317. Written informed consent was obtained from all participants before study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}